Patient Recruitment and Patient Retention

Patient Recruitment Services and Patient Retention Services Market (3rd Edition) by Patient Recruitment Step (Pre-screening and Screening), Trial Phase (Phase I, Phase II, Phase III and Phase IV) Therapeutic Area (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders, Dermatological Disorders, Ophthalmic Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World), Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2022

  • Pages
    185

  • View Count
    24880

  • Buy Now

Example Insights

Patient-Recruitment-and-Retention-Services-Market-Context-thumb Patient-Recruitment-and-Retention-Services-Market-Service-Providers-thumb Patient-Recruitment-and-Retention-Services-Market-Distribution-by-location-thumb
Patient-Recruitment-and-Retention-Services-Market-Distribution-by-Geographical-Reach-thumb Patient-Recruitment-and-Retention-Services-Market-Key-Offerings-thumb Patient-Recruitment-and-Retention-Services-Market-Partnerships-and-Collaborations-thumb
Patient-Recruitment-and-Retention-Services-Market-Future-Growth-Opportunities-thumb Patient-Recruitment-and-Retention-Services-Market-Global-Demand-for-Study-Participants-thumb Patient-Recruitment-and-Retention-Services-Market-Distribution-by-Trial-Phase-thumb
Patient-Recruitment-and-Retention-Services-Market-Insights-from-Primary-Research-thumb    

 

Overview

Due to several factors, such as steady rise in global clinical trials, demand for highly specific study participants, and complex inclusion-exclusion criteria, and the challenges associated with enrolling patients in modern clinical trials, pharmaceutical companies are increasingly using the services of dedicated patient recruitment firms.

-- Chief Operations Officer, Israel-based Small-sized Patient Recruitment Firm

Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. As these trials are prone to delays, and can even fail altogether, they impose an immense financial pressure on sponsors. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, the conduct of such trials is often fraught with challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, owing to the inherent complexity of the overall process and involvement of several different stakeholders, these trials are prone to delays. It is worth mentioning that around 80% of the clinical trials are delayed due to insufficient patient recruitment. Further, retaining patients is also a major concern in pharmaceutical research and development; 15% to 40% of the enrolled patients drop out before the studies are completed, significantly impacting product approvals / launch timelines. Therefore, patient outreach, patient recruitment and patient retention strategies have evolved significantly, especially with the availability of a variety of digital data generation, management and marketing solutions. In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research and patient recruitment. 

Q1. What is the current market landscape of the patient recruitment and patient retention services market?

Amongst several known challenges, patient recruitment is considered to be one of the rate limiting steps when it comes to getting drugs to the market. Presently, more than 155 companies have the required capabilities to offer patient recruitment services and patient retention services across different geographical locations. Such service providers employ a variety of outreach methods and, over time, have attained a vital role in the successful conduct of clinical research. Further, several contract service providers are entering into strategic alliances in order to enhance their respective capabilities and offer an expanded portfolio of services to their clients. 

Q2. How has outsourcing evolved in the patient recruitment and patient retention domain?

Several small and mid-sized players do not have dedicated patient enrolment teams and lack the necessary capabilities / expertise to successfully recruit desired number of patients in clinical trials. In some cases, the clinical studies are too large or geographically broad to be managed by internal staff. Further, the stringent ethical and regulatory guidelines associated with patient enrollment in trials impose a significant burden on drug developers. As a result, outsourcing has become a popular operating model with regards to patient recruitment and patient retention; several specialty service providers, with expertise and experience in this domain, are driving the growth of this upcoming segment of the healthcare market. The advantages of engaging contract service providers are numerous and enable sponsors to meet their clinical research timelines and thereby, launch respective offerings as planned. 

Q3. What are the recent developments and expected trends in the patient recruitment and patient retention domain?

Over the past decade, the patient recruitment and patient retention industry has witnessed tremendous increase in the use of social media platforms, including Facebook, Instagram, Pinterest, LinkedIn and Twitter, and mobile applications for engaging and recruiting patients in clinical studies; these approaches are cost-effective and can be used to connect with diverse and hard-to-reach patient populations. In pursuit of capability and competence improvements, several service providers have also begun adopting and implementing modern technical strategies, such as Electronic Health Records (EHRs) and Real-World Evidence (RWE) for patient enrolment; these novel methods tend to be more efficient and yield a narrow pool of potentially eligible participants for targeted mailings.

Q4. What are the key challenges faced by patient recruitment and patient retention service providers?

The primary challenge faced by patient recruitment and patient retention service providers is the lack of awareness amongst individuals regarding the clinical studies and the benefits offered to study participants. Further, pharmaceutical companies do not allocate adequate budget for carrying out the patient enrolment process. Specifically for clinical trials evaluating orphan drugs and personalized therapies, finding the specialized pool of eligible patients is a burdensome and costly task. Other challenges in this domain include fear of individuals about the adverse events associated with clinical trials, lack of communication between study participants and researchers due to language barrier, and large geographical distance between the patient’s residence and study site, which affect the participation and patient retention in research studies. 

Q5. What are the key value drivers in the patient recruitment and patient retention service market?

Owing to rise in the number of clinical trials that seek to enroll millions of patients, and complexities associated with patient accrual, drug developers are likely to outsource the patient recruitment and patient retention process to service providers. Moreover, we believe that increase in clinical development activity in emerging markets, availability of one-stop patient recruitment service providers, and stringent regulations related to patient enrollment are likely to provide further impetus to the patient recruitment services market.

Q6. What is the current market scenario and likely growth associated with patient recruitment services domain?

The patient recruitment services market is anticipated to grow at a steady pace in the coming years. Owing to the need for large and diverse patient populations, phase III trials are anticipated to be responsible for the maximum share of revenues within this domain. Currently, in terms of therapeutic area, the market is captured by patient recruitment projects for trials evaluating drugs intended for the treatment of cardiovascular disorders. However, this trend is likely to change in the foreseen future with the rising clinical trials focusing on therapeutics targeting oncological disorders. Specifically, in terms of geography, the patient recruitment services market in Asia Pacific is likely to grow at a relatively faster pace in the long term.

Scope of the Report

The “Patient Recruitment Services and Patient Retention Services Market (3rd Edition), 2022-2035: Distribution by Therapeutic Area (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders, Dermatological Disorders, Ophthalmic Disorders and Others), Patient Recruitment Step (Pre-screening and Screening), Trial Phase (Phase I, Phase II, Phase III and Phase IV) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World” report features an extensive study of the current market landscape and future potential of the patient recruitment and patient retention services market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:

  • A general overview of the clinical trials, featuring information on the different phases of clinical trials and their importance. The chapter also lays emphasis on patient recruitment process, its associated challenges and the different strategies used to enhance patient enrolment in clinical research studies. It also presents information on the affiliated ethical considerations and outsourcing activity in this domain. Further, it features an elaborate discussion on the various patient recruitment associated services offered by contract service providers as well as the patient retention strategies employed to prevent drop-out of enrolled individuals from clinical trials.
  • A brief information on the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials. Further, the chapter highlights the various advantages and limitations of these outreach methods.
  • A detailed assessment of the overall landscape of companies offering patient recruitment and patient retention services, along with the information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, patient recruitment and patient retention services offered, patient outreach methods (social media outreach, traditional media outreach, directly approaching individual patients, leveraging proprietary patient databases, exploiting patient communities and advocacy groups, engaging local enrolment specialists, using digital advertising solutions, organizing large scale events / campaigns and exploiting real world data sources), number of patient outreach methods (less than 3 methods, 3 to 6 methods and more than 6 methods), patient recruitment associated service(s) offered (pre-screening potential study participants, study feasibility / protocol development, site identification and selection, project management, site management, IRB/EC submission, core CRO services, clinical monitoring, web development solutions, clinical trial data management, real-time enquiry / information support and investigator grant management), number of patient recruitment associated service(s) offered (less than 3 associated services, 3 to 6 associated services and more than 6 associated services), patient retention method(s) used (dedicated patient engagement solutions, offering study-branded amenities / education materials and offering transportation (to site) support), number of patient retention method(s) used (less than 2 methods, 2 to 5 methods and more than 5 methods), geographical reach (North America, Europe, Asia-Pacific and Rest of the World), therapeutic expertise (respiratory disorders, gastrointestinal disorders, healthy volunteers, cardiovascular disorders, central nervous system and mental health disorders, metabolic disorders, dermatological disorders, oncological disorders, musculoskeletal disorders, infectious diseases, autoimmune disorders, ophthalmic disorders, medical devices, rare diseases / personalized therapies and others). The chapter also covers details on the payment model, patient recruitment platforms / technologies used and the various certifications / accreditations awarded by regulatory bodies.
  • A detailed competitiveness analysis of patient recruitment and patient retention service providers, taking into consideration supplier strength (based on their experience in this field) and service strength (based on number of patient outreach methods, number of patient recruitment associated service(s) offered, number of patient retention method(s) used, geographical reach and therapeutic expertise).
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) offering patient recruitment and patient retention services, across North America, Europe, and Asia-Pacific and Rest of the World. Each profile features a brief overview of the company, along with details related to its patient recruitment and patient retention service portfolio, recent developments and an informed future outlook.
  • An insightful analysis of the recent collaborations within the patient recruitment and patient retention industry, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, mergers, patient recruitment agreements, service alliances, technology development agreements, technology licensing agreements and others), focus area (clinical trial management, patient recruitment and patient retention), therapeutic area (autoimmune disorders, cardiovascular disorders, CNS disorders, dermatological disorders, metabolic disorders, oncological disorders, pain, rare diseases, respiratory disorders,  and others), most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2013-2022.
  • A review of the emerging trends in the patient recruitment industry, including the use of social media, mobile technologies, electronic health records (EHR), real-world evidence (RWE) and artificial intelligence, to overcome the challenges associated with patient enrolment and retention.
  • A detailed discussion on the key growth opportunities (such as rise in the number of clinical trials, development of personalized medicines / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions, stringent regulations related to patient enrollment and technological advancements in clinical trial conduct) in the field of patient recruitment and patient retention that are likely to impact the evolution of the market over the coming years.
  • A case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, regulatory framework for patient recruitment, ethics committees in different countries and documents reviewed by the ethics committees.
  • A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods being used to recruit and the key players engaged in this field.
  • A detailed analysis of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
  • A detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and patient retention services market. In addition, it features various strategies that different companies adopted in order to mitigate the challenges associated with patient recruitment faced during the global crisis.

One of the key objectives of the report was to evaluate the current opportunity and the future growth potential of the patient recruitment and patient retention services market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features a likely distribution of the current and forecasted opportunity across important parameters, such as [A] patient recruitment steps (pre-screening and screening), [B] trial phase (phase I, phase II, phase III and phase IV), [C] therapeutic area (cardiovascular disorders, oncological disorders, infectious diseases, CNS disorders, respiratory disorders, haematological disorders, metabolic disorders, dermatological disorders, ophthalmic disorders and others) and [D] key geographies (North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America and Rest of the World). 

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. 

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Susan Fitzpatrick-Napier (Founder and Director, TrialWire)
  • Kate Shaw (Chief Executive Officer and Founder) and Marco Lassandro (Marketing and Communications Manager, Innovative Trials)
  • Simon Klaasen (Co-founder and Managing Director, Link2Trials)
  • Stefan Mayer-Eggersmann (Chief Commercial Officer, Clariness)
  • Ken Shore (Chief Commercial Officer, Continuum Clinical)
  • Hagit Nof (Chief Operation Officer and Business Development Officer, nRollmed)
  • Paul Ivsin (Ex-Managing Director, Seeker Health)
  • Kasturi Lakhe (Inside Sales Specialist, EVERSANA)

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Clinical Trials
3.2.1 Clinical Trial Phases
3.3. Patient Recruitment in Clinical Trials
3.3.1. Patient Recruitment Process
3.3.2. Challenges Associated with Patient Recruitment
3.3.3. Strategies to Improve Patient Recruitment
3.3.4. Ethical Considerations

3.4. Outsourcing Patient Recruitment
3.4.1. Patient Recruitment-related Services

3.5. Patient Retention
3.5.1. Patient Retention-related Services

3.6. Concluding Remarks

4. PATIENT OUTREACH METHODS
4.1. Chapter Overview
4.2. Patient Outreach Methods
4.2.1. Traditional Patient Outreach Methods
4.2.1.1. Physician Referrals
4.2.1.2. Television
4.2.1.3. Radio
4.2.1.4. Print Media
4.2.1.5. Direct Mail Campaign
4.2.1.6. Cold Call / Call Centre
4.2.1.7. Advantages and Limitations of Traditional Media

4.2.2. Emerging Patient Outreach Methods
4.2.2.1. Social Media
4.2.2.1.1. Geo-Social Media
4.2.2.1.2. Social Networking Websites
4.2.2.1.3. Advantages and Limitations of Social Media
4.2.2.2. Mobile / Software Applications
4.2.2.3. Patient Networks
4.2.2.4. Patient Advocacy Groups
4.2.2.5. Electronic Medical Records (EMRs) / Electronic Health Records (EHRs) and Other Health Registries
4.2.2.6. Search Engine Marketing / Artificial Intelligence-based Marketing
4.2.2.7. Over-the-top (OTT) Media Platforms
4.2.2.8. Indication Specific Events for Patients

4.2.3. Best Practices / Recommendations for Patient Outreach

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Patient Recruitment and Retention Service Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment 
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters  
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Patient Recruitment and Retention Services Offered
5.2.6. Analysis by Patient Outreach Methods
5.2.7. Analysis by Patient Recruitment Associated Service(s) Offered
5.2.8. Analysis by Patient Retention Method(s) Used
5.2.9. Analysis by Geographical Reach
5.2.10. Analysis by Therapeutic Expertise
5.2.11. Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Patient Recruitment and Retention Service Providers: Company Competitiveness Analysis
6.4.1. Competitiveness Analysis: Small Companies
6.4.2. Competitiveness Analysis: Mid-Sized Companies
6.4.3. Competitiveness Analysis: Large and Very Large Companies

7. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. BBK Worldwide (A Publicis Health Company)
7.2.1. Company Overview
7.2.2. Patient Recruitment and Retention Services Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Continuum Clinical
7.3.1. Company Overview
7.3.2. Patient Recruitment and Retention Services Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. IQVIA
7.4.1. Company Overview
7.4.2. Patient Recruitment and Retention Services Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. United BioSource (UBC)
7.5.1. Company Overview
7.5.2. Patient Recruitment and Retention Services Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. WCG ThreeWire
7.6.1. Company Overview
7.6.2. Patient Recruitment and Retention Services Portfolio
7.6.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN EUROPE
8.1. Chapter Overview
8.2. Clariness
8.2.1. Company Overview
8.2.2. Patient Recruitment and Retention Services Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. Ignite Data
8.3.1. Company Overview
8.3.2. Capsule Communications: Patient Recruitment and Retention Services Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. Innovative Trials
8.4.1. Company Overview
8.4.2. Patient Recruitment and Retention Services Portfolio
8.4.3. Recent Developments and Future Outlook

8.5. One Research
8.5.1. Company Overview
8.5.2. Patient Recruitment and Retention Services Portfolio
8.5.3. Recent Developments and Future Outlook

8.6. Orphan Reach
8.6.1. Company Overview
8.6.2. Patient Recruitment and Retention Services Portfolio
8.6.3. Recent Developments and Future Outlook

9. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN ASIA-PACIFIC AND REST OF THE WORLD
9.1. Chapter Overview
9.2. 3H Medi Solution
9.2.1. Company Overview
9.2.2. Patient Recruitment and Retention Services Portfolio
9.2.3. Recent Developments and Future Outlook

9.3. Buzzreach
9.3.1. Company Overview
9.3.2. Patient Recruitment and Retention Services Portfolio
9.3.3. Recent Developments and Future Outlook

9.4. Current Medical Information Center (CMIC)
9.4.1. Company Overview
9.4.2. Patient Recruitment and Retention Services Portfolio
9.4.3. Recent Developments and Future Outlook

9.5. nRollmed
9.5.1. Company Overview
9.5.2. Patient Recruitment and Retention Services Portfolio
9.5.3. Recent Developments and Future Outlook

9.6. Trialfacts
9.6.1. Company Overview
9.6.2. Patient Recruitment and Retention Services Portfolio
9.6.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Patient Recruitment and Retention Services: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Year of Partnership and Focus Area
10.3.6. Analysis by Therapeutic Area
10.3.7. Analysis by Type of Partner
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intracontinental and Intercontinental Deals
10.3.9.2. International and Local Deals

11. RECENT TRENDS IN PATIENT RECRUITMENT AND RETENTION
11.1. Chapter Overview
11.1.1. Campaigning on Social Media to Accelerate Patient Recruitment in Clinical Trials
11.1.2. Adoption of Mobile Technologies for Patient Recruitment and Retention
11.1.3. Use of EHR Data to Improve Patient Recruitment Rates
11.1.4. Use of Other Real-World Data Sources to Overcome Patient Enrolment-related Challenges
11.1.5. Use of Artificial Intelligence to Improve Patient Selection
11.1.6. Increase in Adoption of the Virtual Trial Model During the COVID-19 Pandemic
11.1.7. Growing Focus on Conducting Clinical Research in Emerging Markets

12. FUTURE GROWTH OPPORTUNITIES IN PATIENT RECRUITMENT
12.1. Chapter Overview
12.2. Continuous Rise in the Number of Global Clinical Trials
12.3. Rise in Demand for Orphan Drugs and Personalized Medicine
12.4. Increase in Offshoring Clinical Development Activity to Emerging Regions
12.5. Availability of Service Providers Offering One-Stop-Solutions
12.6. Stringent Regulations and Complex Study Protocols Prompting More Outsourcing
12.7. Impact of the COVID-19 Pandemic on Clinical Research Activity
12.8. Technological Advances in Clinical Trial Conduct

13. CASE STUDY: REGULATORY LANDSCAPE OF PATIENT RECRUITMENT
13.1. Chapter Overview
13.2. Regulatory Framework of Patient Recruitment
13.3. Regulations Involved in Patient Recruitment
13.3.1. ICH-GCP Guidelines
13.3.2. Declaration of Helsinki
13.3.3. General Data Privacy Regulation (GDPR)
13.3.4. Health Insurance Portability and Accountability Act (HIPAA)

14. PATIENT RECRUITMENT IN TRIALS FOCUSED ON PERSONALIZED MEDICINES AND RARE DISEASES
14.1. Chapter Overview
14.2. Clinical Trials Focused on Personalized Medicines and Rare Diseases
14.2.1. Key Challenges
14.2.2. Specialized Patient Outreach Methods
14.2.3. Key Players

15. ANALYSIS OF DEMAND FOR CLINICAL TRIAL PARTICIPANTS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year and Enrolled Patient Population
15.3.2. Analysis by Trial Phase

15.4. Global Demand for Clinical Trial Participants
15.4.1. Analysis by Enrolled Patient Population
15.4.2. Analysis by Trial Phase
15.4.3. Analysis by Therapeutic Area
15.4.4. Analysis by Enrolled Patient Population and Geography

16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Global Patient Recruitment Services Market, 2022-2035
16.4. Patient Recruitment Services Market: Analysis by Patient Recruitment Steps, 2022-2035
16.5. Patient Recruitment Services Market: Analysis by Trial Phase, 2022-2035
16.6. Patient Recruitment Services Market: Analysis by Therapeutic Area, 2022-2035

16.7. Patient Recruitment Services Market: Analysis by Geography, 2022-2035
16.7.1. Patient Recruitment Services: Market Attractiveness Analysis by Country, 2022-2035
16.7.2. Patient Recruitment Services Market in North America, 2022-2035
16.7.2.1. Patient Recruitment Services Market in the US: Analysis by Trial Phase, 2022-2035
16.7.2.2. Patient Recruitment Services Market in the US: Analysis by Therapeutic Area, 2022-2035
16.7.2.3. Patient Recruitment Services Market in Canada: Analysis by Trial Phase, 2022-2035
16.7.2.4. Patient Recruitment Services Market in Canada: Analysis by Therapeutic Area, 2022-2035

16.7.3. Patient Recruitment Services Market in Europe, 2022-2035
16.7.3.1. Patient Recruitment Services Market in Germany: Analysis by Trial Phase, 2022-2035
16.7.3.2. Patient Recruitment Services Market in Germany: Analysis by Therapeutic Area, 2022-2035
16.7.3.3. Patient Recruitment Services Market in France: Analysis by Trial Phase, 2022-2035
16.7.3.4. Patient Recruitment Services Market in France: Analysis by Therapeutic Area, 2022-2035
16.7.3.5. Patient Recruitment Services Market in the UK: Analysis by Trial Phase, 2022-2035
16.7.3.6. Patient Recruitment Services Market in the UK: Analysis by Therapeutic Area, 2022-2035
16.7.3.7. Patient Recruitment Services Market in Italy: Analysis by Trial Phase, 2022-2035
16.7.3.8. Patient Recruitment Services Market in Italy: Analysis by Therapeutic Area, 2022-2035
16.7.3.9. Patient Recruitment Services Market in Spain: Analysis by Trial Phase, 2022-2035
16.7.3.10. Patient Recruitment Services Market in Spain: Analysis by Therapeutic Area, 2022-2035
16.7.3.11. Patient Recruitment Services Market in Rest of Europe: Analysis by Trial Phase, 2022-2035
16.7.3.12. Patient Recruitment Services Market in Rest of Europe: Analysis by Therapeutic Area, 2022-2035

16.7.4. Patient Recruitment Services Market in Asia-Pacific, 2022-2035
16.7.4.1. Patient Recruitment Services Market in Japan: Analysis by Trial Phase, 2022-2035
16.7.4.2. Patient Recruitment Services Market in Japan: Analysis by Therapeutic Area, 2022-2035
16.7.4.3. Patient Recruitment Services Market in South Korea: Analysis by Trial Phase, 2022-2035
16.7.4.4. Patient Recruitment Services Market in South Korea: Analysis by Therapeutic Area, 2022-2035
16.7.4.5. Patient Recruitment Services Market in Australia: Analysis by Trial Phase, 2022-2035
16.7.4.6. Patient Recruitment Services Market in Australia: Analysis by Therapeutic Area, 2022-2035
16.7.4.7. Patient Recruitment Services Market in China: Analysis by Trial Phase, 2022-2035
16.7.4.8. Patient Recruitment Services Market in China: Analysis by Therapeutic Area, 2022-2035
16.7.4.9. Patient Recruitment Services Market in India: Analysis by Trial Phase, 2022-2035
16.7.4.10. Patient Recruitment Services Market in India: Analysis by Therapeutic Area, 2022-2035

16.7.5 Patient Recruitment Services Market in Latin America, 2022-2035
16.7.5.1. Patient Recruitment Services Market in Latin America: Analysis by Trial Phase, 2022-2035
16.7.5.2. Patient Recruitment Services Market in Latin America: Analysis by Therapeutic Area, 2022-2035

16.7.6. Patient Recruitment Services Market in Middle East and North Africa, 2022-2035
16.7.6.1. Patient Recruitment Services Market in Middle East and North Africa: Analysis by Trial Phase, 2022-2035
16.7.6.2. Patient Recruitment Services Market in Middle East and North Africa: Analysis by Therapeutic Area, 2022-2035

16.7.7. Patient Recruitment Services Market in Rest of the World, 2022-2035
16.7.7.1. Patient Recruitment Services Market in Rest of the World: Analysis by Trial Phase, 2022-2035
16.7.7.2. Patient Recruitment Services Market in Rest of the World: Analysis by Therapeutic Area, 2022-2035

17. IMPACT OF THE COVID-19 PANDEMIC ON PATIENT RECRUITMENT SERVICES MARKET
17.1. Chapter Overview
17.2. Impact of COVID-19 Pandemic on Clinical Trials
17.2.1. Impact on Opportunity Related to Patient Recruitment Services
17.2.2. Initiatives Undertaken by Key Patient Recruitment and Retention Service Providers
17.2.2.1. Trialspark
17.2.2.2. BBK Worldwide
17.2.2.3. Clariness
17.2.2.4. Clinical Site Services (CSSi)
17.2.2.5. IQVIA
17.3. Key Strategies Adopted to Mitigate the Challenges Associated with Patient Recruitment and Retention

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. TrialWire
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Susan Fitzpatrick-Napier, Founder and Director

19.3. Innovative Trials
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Kate Shaw, Chief Executive Officer and Founder, and Marco Lassandro, Marketing and Communications Manager

19.4. Link2Trials
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Simon Klaasen, Co-Founder and Managing Director

19.5. Clariness
19.5.1. Company Snapshot
19.5.2. Interview Transcript: Stefan Mayer-Eggersmann, Chief Commercial Officer

19.6. Continuum Clinical
19.6.1. Company Snapshot
19.6.2. Interview Transcript: Ken Shore, Chief Commercial Officer

19.7. nRollmed
19.7.1. Company Snapshot
19.7.2. Interview Transcript: Hagit Nof, Chief Operation Officer and Business Development Officer

19.8. Seeker Health
19.8.1. Company Snapshot
19.8.2. Interview Transcript: Paul Ivsin, Ex Managing Director

19.9. EVERSANA
19.9.1. Company Snapshot
19.9.2. Interview Transcript: Kasturi Lakhe, Inside Sales Specialist

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS 

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnership and Collaborations
Figure 2.3 Executive Summary: Analysis of Demand for Clinical Trial Participants
Figure 2.4 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Factors Contributing to Clinical Trial Cost
Figure 3.2 Patient Recruitment Process
Figure 3.3 Factors Influencing Participation in Clinical Trials
Figure 3.4 Reasons for Patient Dropouts from Clinical Studies
Figure 4.1 Patient Outreach: Advantages and Limitations of Traditional Methods
Figure 4.2 Patient Outreach: Advantages and Limitations of Social Media
Figure 5.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
Figure 5.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size 
Figure 5.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment and Retention Services Offered 
Figure 5.7 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
Figure 5.8 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Method(s) 
Figure 5.9 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
Figure 5.10 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Service(s) Offered
Figure 5.11 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
Figure 5.12 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Method(s) Used
Figure 5.13 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
Figure 5.14 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
Figure 6.1 Company Competitiveness Analysis: Small Companies
Figure 6.2 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.3 Company Competitiveness Analysis: Large and Very Large Companies
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 10.10 Partnerships and Collaborations: International and Local Deals
Figure 11.1 Patient Recruitment Services Market: Recent Trends
Figure 12.1 Patient Recruitment Services Market: Future Growth Opportunities
Figure 12.2 Global Clinical Trials Registered, 2000-2022
Figure 13.1 Patient Recruitment: Regulatory Pathway
Figure 13.2 Patient Recruitment: Regulatory Guidelines
Figure 14.1 Key Challenges in Patient Enrolment in Trials Focused on Personalized Medicines
Figure 14.2 Key Challenges in Patient Enrolment in Trials Focused on Rare Diseases
Figure 14.3 Specialized Patient Outreach Methods
Figure 15.1 Analysis of Demand for Clinical Trial Participants: Scope and Methodology
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.4 Global Demand for Clinical Trial Participants: Distribution by Enrolled Patient Population (Million Patients)
Figure 15.5 Global Demand for Clinical Trial Participants: Distribution by Trial Phase (Million Patients)
Figure 15.6 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area (Million Patients)
Figure 15.7 Global Demand for Clinical Trial Participants: Distribution by Geography (Million Patients)
Figure 16.1 Movement of Patients in Patient Recruitment Process
Figure 16.2 Global Patient Recruitment Services Market, 2022-2035 (USD Billion)
Figure 16.3 Patient Recruitment Services Market: Distribution by Patient Recruitment Steps, 2022-2035 (USD Billion)
Figure 16.4 Patient Recruitment Services Market: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.5 Patient Recruitment Services Market: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.6 Patient Recruitment Services Market: Distribution by Geography, 2022-2035(USD Billion)
Figure 16.7 Patient Recruitment Services Market, 2022 and 2035: Market Attractiveness Distribution by Country
Figure 16.8 Patient Recruitment Services Market in North America, 2022-2035 (USD Billion)
Figure 16.9 Patient Recruitment Services Market in the US: Distribution by Trial Phase,2022-2035 (USD Billion)
Figure 16.10 Patient Recruitment Services Market in the US: Distribution by TherapeuticArea, 2022-2035 (USD Billion)
Figure 16.11 Patient Recruitment Services Market in Canada: Distribution by Trial Phase,2022-2035 (USD Billion)
Figure 16.12 Patient Recruitment Services Market in Canada: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.13 Patient Recruitment Services Market in Europe, 2022-2035 (USD Billion)
Figure 16.14 Patient Recruitment Services Market in Germany: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.15 Patient Recruitment Services Market in Germany: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.16 Patient Recruitment Services Market in France: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.17 Patient Recruitment Services Market in France: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.18 Patient Recruitment Services Market in the UK: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.19 Patient Recruitment Services Market in the UK: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.20 Patient Recruitment Services Market in Italy: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.21 Patient Recruitment Services Market in Italy: Distribution by Therapeutic Area,2022-2035 (USD Billion)
Figure 16.22 Patient Recruitment Services Market in Spain: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.23 Patient Recruitment Services Market in Spain: Distribution by Therapeutic Area,2022-2035 (USD Billion)
Figure 16.24 Patient Recruitment Services Market in Rest of Europe: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.25 Patient Recruitment Services Market in Rest of Europe: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.26 Patient Recruitment Services Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 16.27 Patient Recruitment Services Market in Japan: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.28 Patient Recruitment Services Market in Japan: Distribution by Therapeutic Area,2022-2035 (USD Billion)
Figure 16.29 Patient Recruitment Services Market in South Korea: Distribution by Trial Phase,2022-2035 (USD Billion)
Figure 16.30 Patient Recruitment Services Market in South Korea, 2022-2035: Distribution byTherapeutic Area, 2022-2035 (USD Billion)
Figure 16.31 Patient Recruitment Services Market in Australia: Distribution by Trial Phase,2022-2035 (USD Billion)
Figure 16.32 Patient Recruitment Services Market in Australia: Distribution by TherapeuticArea (USD Billion)
Figure 16.33 Patient Recruitment Services Market in China: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.34 Patient Recruitment Services Market in China: Distribution by Therapeutic Area,2022-2035 (USD Billion)
Figure 16.35 Patient Recruitment Services Market in India: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.36 Patient Recruitment Services Market in India: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.37 Patient Recruitment Services Market in Latin America, 2022-2035 (USD Billion)
Figure 16.38 Patient Recruitment Services Market in Latin America: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.39 Patient Recruitment Services Market in Latin America: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.40 Patient Recruitment Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 16.41 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.42 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 16.43 Patient Recruitment Services Market in Rest of the World, 2022-2035 (USD Billion)
Figure 16.44 Patient Recruitment Services Market in Rest of the World: Distribution by Trial Phase, 2022-2035 (USD Billion)
Figure 16.45 Patient Recruitment Services Market in Rest of the World, 2022-2035:Distribution by Therapeutic Area, 2022-2035 (USD Billion)
Figure 18.1 Concluding Remarks: Overall Market Landscape
Figure 18.2 Concluding Remarks: Company Competitiveness Analysis
Figure 18.3 Concluding Remarks: Partnership and Collaborations
Figure 18.4 Concluding Remarks: Analysis of Demand for Clinical Trial Participants
Figure 18.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Key Characteristics of Clinical Trial Phases
Table 4.1 Traditional and Emerging Patient Outreach Methods
Table 5.1 List of Patient Recruitment and Retention Service Providers
Table 5.2 Patient Recruitment and Retention Service Providers: Information on Patient Outreach Methods
Table 5.3 Patient Recruitment and Retention Service Providers: Information on Type of Patient Recruitment Service(s) Offered
Table 5.4 Patient Recruitment and Retention Service Providers: Information on Patient Retention Method(s) Used and Geographical Reach
Table 5.5 Patient Recruitment and Retention Service Providers: Information on Therapeutic Expertise
Table 5.6 Patient Recruitment and Retention Service Providers: Information on Payment Model, Patient Recruitment Technology / Platform and Regulatory Compliance Status
Table 7.1 Leading Patient Recruitment Service Providers in North America
Table 7.2 BBK Worldwide: Company Overview
Table 7.3 BBK Worldwide: Patient Recruitment and Retention Services Portfolio
Table 7.4 BBK Worldwide: Recent Developments and Future Outlook
Table 7.5 Continuum Clinical: Company Overview
Table 7.6 Continuum Clinical: Patient Recruitment and Retention Services Portfolio
Table 7.7 Continuum Clinical: Recent Developments and Future Outlook
Table 7.8 IQVIA: Company Overview
Table 7.9 IQVIA: Patient Recruitment and Retention Services Portfolio
Table 7.10 IQVIA: Recent Developments and Future Outlook
Table 7.11 United BioSource: Company Overview
Table 7.12 United BioSource: Patient Recruitment and Retention Services Portfolio
Table 7.13 United BioSource: Recent Developments and Future Outlook
Table 7.14 WCG ThreeWire: Company Overview
Table 7.15 WCG ThreeWire: Patient Recruitment and Retention Services Portfolio
Table 7.16 WCG ThreeWire: Recent Developments and Future Outlook
Table 8.1 Leading Patient Recruitment Service Providers in Europe
Table 8.2 Clariness: Company Overview
Table 8.3 Clariness: Patient Recruitment and Retention Services Portfolio
Table 8.4 Clariness: Recent Developments and Future Outlook
Table 8.5 Ignite Data: Company Overview
Table 8.6 Ignite Data: Patient Recruitment and Retention Services Portfolio
Table 8.7 Ignite Data: Recent Developments and Future Outlook
Table 8.8 Innovative Trials: Company Overview
Table 8.9 Innovative Trials: Patient Recruitment and Retention Services Portfolio
Table 8.10 Innovative Trials: Recent Developments and Future Outlook
Table 8.11 One Research: Company Overview
Table 8.12 One Research: Patient Recruitment and Retention Services Portfolio
Table 8.13 Orphan Reach: Company Overview
Table 8.14 Orphan Reach: Patient Recruitment and Retention Services Portfolio
Table 8.15 Orphan Reach: Recent Developments and Future Outlook
Table 9.1 Leading Patient Recruitment Service Providers in Asia Pacific and Rest of the World
Table 9.2 3H Medi Solution: Company Overview
Table 9.3 3H Medi Solution: Patient Recruitment and Retention Services Portfolio
Table 9.4 3H Medi Solution: Recent Developments and Future Outlook
Table 9.5 Buzzreach: Company Overview
Table 9.6 Buzzreach: Patient Recruitment and Retention Services Portfolio
Table 9.7 Buzzreach: Recent Developments and Future Outlook
Table 9.8 Current Medical Information Center: Company Overview
Table 9.9 Current Medical Information Center: Patient Recruitment and Retention Services Portfolio
Table 9.10 Current Medical Information Center: Recent Developments and Future Outlook
Table 9.11 nRollmed: Company Overview
Table 9.12 nRollmed: Patient Recruitment and Retention Services PortfolioF
Table 9.13 Trialfacts: Company Overview
Table 9.14 Trialfacts: Patient Recruitment and Retention Services Portfolio
Table 9.15 Trialfacts: Recent Developments and Future Outlook
Table 10.1 Patient Recruitment and Retention Services: List of Partnerships and Collaborations, 2013-2022
Table 14.1 Patient Recruitment Service Providers: List of Trials Focused on Personalized Medicines and Rare Diseases
Table 15.1 Global Demand for Clinical Trial Participants: Average Number of Patients Enrolled by Trial Phase
Table 19.1 TrialWire: Company Snapshot
Table 19.2 Innovative Trials: Company Snapshot
Table 19.3 Link2Trials: Company Snapshot
Table 19.4 Clariness: Company Snapshot
Table 19.5 Continuum Clinical: Company Snapshot
Table 19.6 nRollmed: Company Snapshot
Table 19.7 Seeker Health: Company Snapshot
Table 19.8 EVERSANA: Company Snapshot
Table 20.1 Factors Contributing to Clinical Trial Cost
Table 20.2 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
Table 20.3 Patient Recruitment and Retention Service Providers: Distribution by Company Size
Table 20.4 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 20.5 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 20.6 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
Table 20.7 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment and Retention Services Offered
Table 20.8 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
Table 20.9 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Method(s)
Table 20.10 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
Table 20.11 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Service(s) Offered
Table 20.12 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
Table 20.13 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Method(s) Used
Table 20.14 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
Table 20.15 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
Table 20.16 Partnerships and Collaborations: Distribution by Year of Partnership
Table 20.17 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.18 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 20.19 Partnerships and Collaborations: Distribution by Focus Area
Table 20.20 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
Table 20.21 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 20.22 Partnerships and Collaborations: Distribution by Type of Partner
Table 20.23 Most Active Players: Distribution by Number of Partnerships
Table 20.24 Partnerships and Collaborations: Intracontinental and Intercontinental Distribution
Table 20.25 Partnerships and Collaborations: International and Local Distribution
Table 20.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 20.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 20.28 Global Demand for Clinical Trial Participants: Distribution by Enrolled Patient Population (Million Patients)
Table 20.29 Global Demand for Clinical Trial Participants: Distribution by Trial Phase (Million Patients)
Table 20.30 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area (Million Patients)
Table 20.31 Global Demand for Clinical Trial Participants: Distribution by Geography (Million Patients)
Table 20.32 Global Patient Recruitment Services Market, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.33 Patient Recruitment Services Market: Distribution by Patient Recruitment Steps, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.34 Patient Recruitment Services Market: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.35 Patient Recruitment Services Market: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.36 Patient Recruitment Services Market: Distribution by Geography, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.37 Patient Recruitment Services Market, 2022 and 2035: Market Attractiveness Distribution by Country
Table 20.38 Patient Recruitment Services Market in North America, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.39 Patient Recruitment Services Market in the US: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.40 Patient Recruitment Services Market in the US: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.42 Patient Recruitment Services Market in Canada: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.43 Patient Recruitment Services Market in Canada: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.44 Patient Recruitment Services Market in Europe, 2022-2035 (USD Billion)
Table 20.45 Patient Recruitment Services Market in Germany: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.46 Patient Recruitment Services Market in Germany: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.47 Patient Recruitment Services Market in France: Distribution by Trial Phase,2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.48 Patient Recruitment Services Market in France: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.49 Patient Recruitment Services Market in the UK: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.50 Patient Recruitment Services Market in the UK: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.51 Patient Recruitment Services Market in Italy: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.52 Patient Recruitment Services Market in Italy: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.53 Patient Recruitment Services Market in Spain: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.54 Patient Recruitment Services Market in Spain: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.55 Patient Recruitment Services Market in Rest of Europe: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.56 Patient Recruitment Services Market in Rest of Europe: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.57 Patient Recruitment Services Market in Asia Pacific, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.58 Patient Recruitment Services Market in Japan: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.59 Patient Recruitment Services Market in Japan: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.60 Patient Recruitment Services Market in South Korea: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.61 Patient Recruitment Services Market in South Korea, 2022-2035: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.62 Patient Recruitment Services Market in Australia: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.63 Patient Recruitment Services Market in Australia: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.64 Patient Recruitment Services Market in China: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.65 Patient Recruitment Services Market in China: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.66 Patient Recruitment Services Market in India: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.67 Patient Recruitment Services Market in India: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.68 Patient Recruitment Services Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.69 Patient Recruitment Services Market in Latin America: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.70 Patient Recruitment Services Market in Latin America: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.71 Patient Recruitment Services Market in Middle East and North Africa, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.72 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.73 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.74 Patient Recruitment Services Market in Rest of the World, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.75 Patient Recruitment Services Market in Rest of the World: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
Table 20.76 Patient Recruitment Services Market in Rest of the World, 2022-2035: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in this report:

  1. 23andMe
  2. 3H Medi Solution
  3. 83bar
  4. Academic Network (A Stericycle company)
  5. Accelerated Enrollment Solutions (AES) 
  6. Accellacare (An ICON company)
  7. Access Clinical Research
  8. Accurate Clinical Research
  9. Acurian
  10. Addario Lung Cancer Medical Institute
  11. AdhereTech
  12. Adult Medicine
  13. Affinity Health
  14. AiCure
  15. Alkemy Partners
  16. Alliance Community Healthcare
  17. Allscripts
  18. Amber Specialty
  19. American Liver Foundation
  20. American Research Associates (ARA)
  21. American Society of Clinical Oncology
  22. Amgen
  23. Anteris Bio
  24. Antidote
  25. ApotheCom
  26. Apptomics
  27. AQLANE Medical
  28. Arden & Schmidt
  29. Association of Clinical Research Professionals (ACRP)
  30. ATLAS Medical Services
  31. AutoCruitment
  32. Avacare (An IQVIA company)
  33. AXELLE Group
  34. Axiom Accelerated Patient Recruitment
  35. BBK Worldwide (Acquired by Publicis Health)
  36. BEKHealth
  37. BIApharm 
  38. bioaccess
  39. Bio-Optronics
  40. Biorasi
  41. BioScript
  42. Blueprint Clinical
  43. BlueTheory Clinical Trials
  44. BMC Group
  45. Boehringer Ingelheim
  46. Box
  47. Bridge Clinical Research
  48. Bright Pharmaceutical Services
  49. Buzzreach 
  50. Capsule Communications
  51. Carebox Healthcare Solutions
  52. Carenity (A subsidiary of EvidentIQ Group)
  53. CaringKind
  54. Castor
  55. CCBR-SYNARC
  56. CCT Research
  57. Chase Medical Research
  58. Cinven
  59. Circuit Clinical
  60. Citruslabs
  61. Clara Health (Acquired by M&B Sciences)
  62. Clariness 
  63. ClinEdge
  64. Clinerion
  65. Clinical Accelerator
  66. Clinical Ambassador
  67. Clinical List America
  68. Clinical Site Services (CSSi)
  69. Clinical Trial Marketing Communications (CTMC)
  70. Clinical Trial Media (CTM)
  71. Clinical Trial Networking (CT-N)
  72. ClinicalConnection
  73. Clinically Media
  74. ClinIntel
  75. CliniSpan Health
  76. ClinOpsHub 
  77. Clinrol
  78. Clinspire Research
  79. Clintec (An IQVIA company)
  80. Clintract 
  81. Clinverse
  82. ClinWin Research Services
  83. Cloudbyz 
  84. CMX Research
  85. Compass Research
  86. Continuum Clinical
  87. Credent Partners
  88. CROee
  89. Cromos Pharma
  90. CTC North
  91. CUBRC
  92. Current Medical Information Center (CMIC)
  93. Cytespace
  94. DAC Patient Recruitment Services
  95. Datavant
  96. DAVA Oncology
  97. Deep 6 AI
  98. Deep Lens
  99. DrFirst
  100. Effectus Clinical Trial Recruitment
  101. EGeen
  102. Elligo Health Research
  103. EmergingMed
  104. Emmes
  105. ePatientFinder 
  106. Ergomed 
  107. ESTERN Medical
  108. eStudySite
  109. European Organisation for Research and Treatment of Cancer (EORTC)
  110. EVERSANA
  111. EvidentIQ
  112. Evolution Research Group (ERG)
  113. Evrima Technologies
  114. FDAMap
  115. Fidelis Research
  116. Flatiron Health
  117. FOMAT Medical Research
  118. Fortress Medical Systems
  119. Foundation Medicine
  120. Friends of Cancer Research
  121. Gaea
  122. Galen Patient Recruitment
  123. GCP Clinical Studies
  124. Genentech
  125. Global Clinical Trials
  126. Global Perspectives
  127. Greater Gift
  128. GuideStar Research
  129. Healthjump
  130. HealthMatch 
  131. Healthstar Physicians
  132. HealthVerity
  133. Heron Therapeutics
  134. iClusion
  135. Ignite Data
  136. Illingworth Research Group
  137. IMS Health
  138. Innovaderm
  139. Innovative Trials
  140. Inspire
  141. Institute of Clinical Research India (ICRI)
  142. Integrated Clinical Trial Services (ICTS)
  143. International Research Network (IRN)
  144. Invicro
  145. Invitae
  146. iPatientAxis
  147. IQVIA
  148. IRM
  149. IVR Clinical Concepts (IVRCC)
  150. IZ Medical
  151. J Trotter Research & Consulting (JTRC) 
  152. Jack Nathan Health
  153. JLL Partners
  154. Juno Research
  155. kfgn
  156. KGK Science
  157. Klinische Forschung Berlin
  158. Komplett Clinical Research (KCR)
  159. LabCorp Diagnostics
  160. Langland
  161. LeadSlinger
  162. Leapcure
  163. Limbix
  164. LINEA System
  165. Linical
  166. Linical Americas
  167. Link2Trials
  168. LiveRamp
  169. Lyft
  170. Massive Bio
  171. Matrix Clinical Trials
  172. MedGenome
  173. Medical Research Network (MRN)
  174. MediciGroup
  175. Medicover Integrated Clinical Services (MICS) (A subsidiary of Medicover)
  176. Medidata
  177. Melanoma Research Alliance
  178. Meridian Clinical Research
  179. MMG
  180. Mondosano
  181. Mundipharma Research
  182. Muscular Dystrophy Association (MDA)
  183. National Cancer Institute
  184. National Minority Health Association (NMHA)
  185. Neox 
  186. NextGen Healthcare
  187. Noom
  188. Northumbria Healthcare
  189. NorthWest EHealth
  190. nRollmed
  191. O4 Research
  192. One Research
  193. OptimizeRx
  194. Ora
  195. Orphan Reach (Acquired by Emmes)
  196. Orphanos (A subsidiary of Trial Runners)
  197. Osaka International Cancer Institute
  198. Panacea Patient Recruitment
  199. Panthera Biopartners
  200. Parallel 6 
  201. PAREXEL
  202. Patient Enrollment Advisors
  203. PatientPoint
  204. Patient RM 
  205. PatientCentra
  206. PatientEvolution
  207. Patiro
  208. Pepgra
  209. Pfizer
  210. PharmaCentra
  211. Pharmatech (Acquired by Caris Life Sciences)
  212. Pharm-Olam (Acquired by Allucent)
  213. phaware
  214. Pivotal Patient Journey
  215. Polaris Biopharma Consulting
  216. Practice Fusion
  217. Praxis
  218. PRC Clinical
  219. Precision for Medicine
  220. Profil
  221. Prominis Medical Services
  222. ProRelix Research
  223. Protenium Clinical Research
  224. Pulse Clinical Research
  225. PWNHealth
  226. QPS Miami
  227. Radiant Research
  228. Ravek
  229. RealTime Software Solutions
  230. Reify Health
  231. RemediumOne 
  232. Remedy Health Media
  233. Rep Network
  234. Richmond Pharmacology
  235. Ripple Science
  236. Riverside Medical Group
  237. Roche
  238. Root Health
  239. Roswell Park Comprehensive Cancer Center
  240. RxE2
  241. S4 Research
  242. Sanofi
  243. Sanos Clinic
  244. Science 37
  245. Scientist.com
  246. Seeker Health
  247. Seqster
  248. Servier
  249. Shanghai Jsure Health Technology
  250. Signant Health
  251. Signify Health
  252. SitePartner
  253. SkyCraper Clinical Research Solutions (SkyCrapercrs)
  254. Skylight Health Group
  255. SMO Clinical Research (I) (SMO-India)
  256. SMO ClinPlus
  257. Society for Clinical Research Sites
  258. Spectrum Clinical Research
  259. Splash Clinical
  260. STARR Coalition
  261. Studies&Me (Acquired by Sanos Clinic)
  262. StudyKIK
  263. SubjectWell
  264. Surescripts
  265. Syapse
  266. Syneos Health
  267. Synexus
  268. TFS HealthScience
  269. The Buffalo-Niagara Clinical Alliance (BNCA)
  270. The Christie NHS Foundation Trust
  271. The Foundation for the National Institutes of Health (FNIH)
  272. The Patient Recruiting Agency (TPRA)
  273. Topstone Research
  274. Total Diversity Clinical Trial Management
  275. Trialbee
  276. Trialfacts
  277. TrialJoin
  278. Trials24
  279. TrialSpark
  280. TrialWire
  281. TriNetX
  282. United BioSource (UBC) 
  283. University of Exeter
  284. Velocity Clinical Research
  285. VeraSci
  286. Veristat
  287. Vineti
  288. Viomedo
  289. Viomedo (Acquired by Clariness)
  290. VisibilityRx 
  291. WCCT Global
  292. WCG PatientWise
  293. WCG ThreeWire (A subsidiary of WIRB-Copernicus Group (WCG))
  294. Wefight
  295. Western Washington Medical Group (WWMG)
  296. WorldQuant Predictive
  297. Worldwide Clinical Trials
  298. X Factor Advertising
  299. Xcene Research
  300. xCures

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2022 Roots Analysis. All Rights Reserved.